{"id":837321,"date":"2025-04-15T08:07:29","date_gmt":"2025-04-15T12:07:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-aua-2025-investor-event-agenda\/"},"modified":"2025-04-15T08:07:29","modified_gmt":"2025-04-15T12:07:29","slug":"profound-medical-aua-2025-investor-event-agenda","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-aua-2025-investor-event-agenda\/","title":{"rendered":"Profound Medical AUA 2025 Investor Event Agenda"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">TORONTO, April  15, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LhpaVq32W--IW9gEm-I3R_HSMMltj1Xr6kK-mYg5ZZpYwEqjOwhsVSqYxpPRPFF-oZKull7cQI11E5kaoUMXtF2lKmNNp2SBowoO3I57liA=\" rel=\"nofollow\" target=\"_blank\">Profound Medical Corp.<\/a> (NASDAQ:PROF; TSX:PRN) (\u201cProfound\u201d or the \u201cCompany\u201d), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today additional details regarding its hybrid (in-person and virtual) investor event taking place on Monday, April 28, 2025, during the American Urological Association\u2019s (\u201cAUA\u201d) Annual Meeting.<\/p>\n<p align=\"justify\">The event will be held at the Waldorf Astoria in Las Vegas, NV. The agenda will commence at 3:30 p.m. Pacific Time (6:30 p.m. Eastern Time) and is scheduled to conclude at approximately 5:00 p.m. Pacific Time (8:00 p.m. Eastern Time). The program will feature presentations from members of Profound\u2019s management team as well as by leading physicians.<\/p>\n<p align=\"justify\">Agenda:<\/p>\n<table style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:10%;width:10%;min-width:10%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>TIME (PT)<\/strong>\n          <\/td>\n<td style=\"max-width:35%;width:35%;min-width:35%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>SPEAKER<\/strong>\n          <\/td>\n<td style=\"max-width:55%;width:55%;min-width:55%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>DETAILS<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: top\">3:30 \u2013 3:45 p.m.<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: top\">Mathieu Burtnyk, Ph.D. \u2013 President<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: top\">Welcome and introduction; peri-operative results from the Level 1 CAPTAIN post-market study comparing the TULSA procedure to radical prostatectomy in men with localized prostate cancer<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: top\">3:45 \u2013 4:00 p.m.<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: top\">Ram A. Pathak, M.D. \u2013 Associate Professor in the Department of Urology at Mayo Clinic Florida<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: top\">Dr. Pathak\u2019s experience with TULSA-PRO<sup>\u00ae<\/sup>, including workflow optimization and clinical outcome data<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: top\">4:00 \u2013 4:15 p.m.<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: top\">Arun Menawat, Ph.D. \u2013 CEO and Chairman<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: top\">Two key 2025 programs: TULSA-AI<sup>\u00ae<\/sup>module for benign prostatic hyperplasia (\u201cBPH\u201d), including a live demonstration of the technology; and TULSA+, combining TULSA-PRO<sup>\u00ae<\/sup>system and consumables with Siemens Healthineers\u2019 Magnetom Free.Max interventional MRI as a total prostate solution<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: top\">4:15 \u2013 4:25 p.m.<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: top\">Naveen Kella, M.D. \u2013 Founder of The Urology Place and an Adjunct Assistant Professor for the UT Health Science Center San Antonio<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: top\">TULSA procedure\u2019s ability to safely, effectively and efficiently treat BPH, present and future<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: top\">4:25 \u2013 4:40 p.m.<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: top\">Tom Tamberrino \u2013 Chief Commercial Officer<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: top\">TULSA+ program business model, benefits, targets and commercial plans<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: top\">4:40 \u2013 5:00 p.m.<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: left;vertical-align: middle;vertical-align: top\">Q&amp;A<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\u00a0<br \/>For those attending the event in-person, advance registration is required using this <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M6VTWO-tiZmYA0x-JqnWVleZfeGWT-P-mNXI2hCRs6PAmNGKVuVVqcc4Aybqokef_tTPgMaiIwbUoN-iGag6Upf8ZQxyIve3t0trLk9vfRE=\" rel=\"nofollow\" target=\"_blank\"><strong>LINK<\/strong><\/a>.<\/p>\n<p align=\"justify\">A live and archived webcast will also be available on the Company\u2019s <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NPy3HazHb5BQVjVOg_6JN7ON_ZBCse4I_y3KGBLQzYoEawpgSvID5ylKLEBcSW1XP8sTEP51eEZJiI9f2Y_KSQ==\" rel=\"nofollow\" target=\"_blank\"><strong>website<\/strong><\/a> under \u201cWebcasts\u201d in the Investors section.<\/p>\n<p align=\"justify\">\n        <strong>About Profound Medical Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.<\/p>\n<p align=\"justify\">Profound is commercializing TULSA-PRO<sup>\u00ae<\/sup>, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO<sup>\u00ae<\/sup> system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (\u201cBPH\u201d); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. TULSA employs real-time MR guidance for precision to preserve patients\u2019 urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57\u00b0C. TULSA is an incision- and radiation-free \u201cone-and-done\u201d procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO<sup>\u00ae<\/sup> is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (\u201cFDA\u201d).<\/p>\n<p align=\"justify\">Profound is also commercializing Sonalleve<sup>\u00ae<\/sup>, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve<sup>\u00ae<\/sup> has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve<sup>\u00ae<\/sup> where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the efficacy of Profound\u2019s technology in the treatment of prostate cancer, BPH, uterine fibroids, palliative pain treatment and osteoid osteoma; and the success of Profound\u2019s U.S. commercialization strategy and activities for TULSA-PRO<sup>\u00ae<\/sup>. Often, but not always, forward-looking statements can be identified by the use of words such as &#8220;plans&#8221;, &#8220;is expected&#8221;, &#8220;expects&#8221;, &#8220;scheduled&#8221;, &#8220;intends&#8221;, &#8220;contemplates&#8221;, &#8220;anticipates&#8221;, &#8220;believes&#8221;, &#8220;proposes&#8221; or variations (including negative variations) of such words and phrases, or state that certain actions, events or results &#8220;may&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;might&#8221; or &#8220;will&#8221; be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, regulatory approvals, reimbursement, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Other factors and risks that may cause actual results to differ materially from those set out in the forward-looking statements are described in Profound&#8217;s Annual Report on Form 10-K and other filings made with U.S. and Canadian securities regulators, available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EvdoccAbWNHPC1eiii8Tbuub5LJim6EcJ6gi1GcDT1VMPrm_YURvcxrkQK37mRp4T0u5kmFmss6ENR_RZiYPbdhknEoMyd-HFhFyf6mneD4=\" rel=\"nofollow\" target=\"_blank\">www.sedarplus.ca<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EvdoccAbWNHPC1eiii8TbhydbHVj4GAHspo-JPH2cWfzzZV-d5-7MOOV-m3QbfiOIFqPptA8x0Yxn2v7sf57mQ==\" rel=\"nofollow\" target=\"_blank\">www.sec.gov<\/a>. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.<\/p>\n<p align=\"justify\">\n        <strong>For further information, please contact:<\/strong><br \/>\n        <br \/>Stephen Kilmer<br \/>Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GonbE1RHG9QOyqa-PmltNt9r7yuEqI4pAMz-vj6WQ98hYNi2rpGXzbiISQLzmDchiadS4q4zJ3e6qpxR8_udadU-wJ_DkeodVRy1lrdQw0y1iWe5IUBU9-BcpEttpQ-J\" rel=\"nofollow\" target=\"_blank\">skilmer@profoundmedical.com<\/a><br \/>T: 647.872.4849<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjYzNiM2ODY3MzI5IzIwMTg1NDc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MGNhYmNkOWYtYTIwNi00M2YxLWI2MDctMjc1MWViMzg4MGRmLTEwMzAxMTktMjAyNS0wNC0xNS1lbg==\/tiny\/Profound-Medical-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>TORONTO, April 15, 2025 (GLOBE NEWSWIRE) &#8212; Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (\u201cProfound\u201d or the \u201cCompany\u201d), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today additional details regarding its hybrid (in-person and virtual) investor event taking place on Monday, April 28, 2025, during the American Urological Association\u2019s (\u201cAUA\u201d) Annual Meeting. The event will be held at the Waldorf Astoria in Las Vegas, NV. The agenda will commence at 3:30 p.m. Pacific Time (6:30 p.m. Eastern Time) and is scheduled to conclude at approximately 5:00 p.m. Pacific Time (8:00 p.m. Eastern Time). The program will feature presentations from members of Profound\u2019s management team as well as by leading physicians. Agenda: &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-aua-2025-investor-event-agenda\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Profound Medical AUA 2025 Investor Event Agenda&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-837321","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Profound Medical AUA 2025 Investor Event Agenda - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-aua-2025-investor-event-agenda\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Profound Medical AUA 2025 Investor Event Agenda - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TORONTO, April 15, 2025 (GLOBE NEWSWIRE) &#8212; Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (\u201cProfound\u201d or the \u201cCompany\u201d), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today additional details regarding its hybrid (in-person and virtual) investor event taking place on Monday, April 28, 2025, during the American Urological Association\u2019s (\u201cAUA\u201d) Annual Meeting. The event will be held at the Waldorf Astoria in Las Vegas, NV. The agenda will commence at 3:30 p.m. Pacific Time (6:30 p.m. Eastern Time) and is scheduled to conclude at approximately 5:00 p.m. Pacific Time (8:00 p.m. Eastern Time). The program will feature presentations from members of Profound\u2019s management team as well as by leading physicians. Agenda: &hellip; Continue reading &quot;Profound Medical AUA 2025 Investor Event Agenda&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-aua-2025-investor-event-agenda\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-15T12:07:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjYzNiM2ODY3MzI5IzIwMTg1NDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profound-medical-aua-2025-investor-event-agenda\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profound-medical-aua-2025-investor-event-agenda\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Profound Medical AUA 2025 Investor Event Agenda\",\"datePublished\":\"2025-04-15T12:07:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profound-medical-aua-2025-investor-event-agenda\\\/\"},\"wordCount\":986,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profound-medical-aua-2025-investor-event-agenda\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMjYzNiM2ODY3MzI5IzIwMTg1NDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profound-medical-aua-2025-investor-event-agenda\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profound-medical-aua-2025-investor-event-agenda\\\/\",\"name\":\"Profound Medical AUA 2025 Investor Event Agenda - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profound-medical-aua-2025-investor-event-agenda\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profound-medical-aua-2025-investor-event-agenda\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMjYzNiM2ODY3MzI5IzIwMTg1NDc=\",\"datePublished\":\"2025-04-15T12:07:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profound-medical-aua-2025-investor-event-agenda\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profound-medical-aua-2025-investor-event-agenda\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profound-medical-aua-2025-investor-event-agenda\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMjYzNiM2ODY3MzI5IzIwMTg1NDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMjYzNiM2ODY3MzI5IzIwMTg1NDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profound-medical-aua-2025-investor-event-agenda\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Profound Medical AUA 2025 Investor Event Agenda\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Profound Medical AUA 2025 Investor Event Agenda - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-aua-2025-investor-event-agenda\/","og_locale":"en_US","og_type":"article","og_title":"Profound Medical AUA 2025 Investor Event Agenda - Market Newsdesk","og_description":"TORONTO, April 15, 2025 (GLOBE NEWSWIRE) &#8212; Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (\u201cProfound\u201d or the \u201cCompany\u201d), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today additional details regarding its hybrid (in-person and virtual) investor event taking place on Monday, April 28, 2025, during the American Urological Association\u2019s (\u201cAUA\u201d) Annual Meeting. The event will be held at the Waldorf Astoria in Las Vegas, NV. The agenda will commence at 3:30 p.m. Pacific Time (6:30 p.m. Eastern Time) and is scheduled to conclude at approximately 5:00 p.m. Pacific Time (8:00 p.m. Eastern Time). The program will feature presentations from members of Profound\u2019s management team as well as by leading physicians. Agenda: &hellip; Continue reading \"Profound Medical AUA 2025 Investor Event Agenda\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-aua-2025-investor-event-agenda\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-15T12:07:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjYzNiM2ODY3MzI5IzIwMTg1NDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-aua-2025-investor-event-agenda\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-aua-2025-investor-event-agenda\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Profound Medical AUA 2025 Investor Event Agenda","datePublished":"2025-04-15T12:07:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-aua-2025-investor-event-agenda\/"},"wordCount":986,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-aua-2025-investor-event-agenda\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjYzNiM2ODY3MzI5IzIwMTg1NDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-aua-2025-investor-event-agenda\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-aua-2025-investor-event-agenda\/","name":"Profound Medical AUA 2025 Investor Event Agenda - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-aua-2025-investor-event-agenda\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-aua-2025-investor-event-agenda\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjYzNiM2ODY3MzI5IzIwMTg1NDc=","datePublished":"2025-04-15T12:07:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-aua-2025-investor-event-agenda\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-aua-2025-investor-event-agenda\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-aua-2025-investor-event-agenda\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjYzNiM2ODY3MzI5IzIwMTg1NDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjYzNiM2ODY3MzI5IzIwMTg1NDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-aua-2025-investor-event-agenda\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Profound Medical AUA 2025 Investor Event Agenda"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/837321","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=837321"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/837321\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=837321"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=837321"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=837321"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}